CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Renovacor Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Renovacor Inc
201 Broadway, Suite 310
Phone: (610) 424-2650p:610 424-2650 CAMBRIDGE, MA  02139  United States Fax: (302) 655-5049f:302 655-5049

This company was Merged or Acquired on 12/1/2022.
This company ceased filing statements with the SEC on 12/12/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Renovacor, Inc. is a preclinical-stage gene therapy company. The Company is engaged in developing a pipeline of adeno-associated virus (AAV)-based gene therapies for Bcl2-associated athanogene 3 (BAG3) gene mutation-associated diseases in areas of unmet medical need. The Company's therapeutic focuses on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy. Its lead product candidate, REN-001, is an AAV9-based gene therapy designed to treat BAG3-associated dilated cardiomyopathy (DCM). The Company is also conducting preclinical studies exploring the ability of a BAG3 gene therapy to treat patients suffering from DCM caused by BAG3 haploinsufficiency. The Company’s preclinical strategy is to advance earlier stage research programs of its BAG3 gene therapy. Its research and discovery programs include BAG3- mediated diseases associated with the cardiovascular system and the central nervous system.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202212/31/2021YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
6770 Blank checks

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer MagdaleneCook 48 9/1/2021 9/1/2021
Chief Financial Officer Wendy F.DiCicco 54 6/2/2022
Senior Vice President - Operations, Chief Business Officer ElizabethWhite
8 additional Officers and Directors records available in full report.

Business Names
Business Name
CHAQ
CHAQ U
CHAQ.U
4 additional Business Names available in full report.

General Information
Number of Employees: 19 (As of 12/31/2021)
Outstanding Shares: 17,269,415 (As of 11/10/2022)
Shareholders: 27
Stock Exchange: ASE
Federal Tax Id: 830802155
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, July 3, 2024